NephroGenex is a US-based pharmaceuticals company that focuses on developing therapeutics to treat kidney diseases caused by pathogenic oxidative chemistries.
In the initial public offering (IPO) they offered the shares at $12 each. They are listed on the Nasdaq as NRX. and the shares generated a gross income of $37.2m.
Aegis Capital Corporation acted as sole book-running manager for the IPO. NephroGenex has granted the underwriter a 45-day option to purchase an additional 465,000 shares of common stock to cover over-allotments.
Shareholders in the NephroGenex include Care Capital (59.9% pre-IPO stake), Rho Ventures (23.1%) and BioStratum(9.4%).